Last reviewed · How we verify
NCT05447949
Dexmedetomidine Versus Dexamethasone as Adjuncts in Erector Spinae Plane Block in Modified Radical Mastectomy
NA trial testing Adjuncts to levobupivacaine in Erector Spinae Plane Block in Breast Cancer in 90 participants. Completed in 15 March 2022.
15 March 2022
Quick facts
| Lead sponsor | National Cancer Institute, Egypt |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 90 |
| Start date | 15 December 2020 |
| Primary completion | 15 March 2022 |
| Estimated completion | 15 March 2022 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Adjuncts to levobupivacaine in Erector Spinae Plane Block
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Post Operative Pain — all drugs for Post Operative Pain →
Sponsor
National Cancer Institute, Egypt
Who can join
Adults 18 to 65, female only, with Breast Cancer or Post Operative Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the analgesic efficacy and safety of adding dexmedetomidine versus dexamethasone to levobupivacaine in ultrasound guided ESPB for patients undergoing modified radical mastectomy
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05447949
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other National Cancer Institute, Egypt trials
Trials by the same sponsor.
- NCT07424638 — Interscalene Block Versus Anterior Suprascapular Block for Post-Thoracotomy Shoulder Pain · NA · recruiting
- NCT07367568 — Costotransverse Foramen Block With Erector Spinae Plane Block in Modified Radical Mastectomy · NA · recruiting
- NCT07367581 — Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer · NA · recruiting
- NCT07337330 — Ultrasound Guided External Oblique Intercostal Plane Block Versus Erector Spinae Block for Post Hepatectomy Pain · NA · not yet recruiting
- NCT07390448 — Rhomboid Intercostal Sub-serratus Plane Blocks and Erector Spinae Plane Block in Mastectomy Surgeries · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05447949 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute, Egypt
- Last refreshed: 7 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05447949.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing